30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Multiple Myeloma
Primary: Overall Response Rate — 95 percentage of participants
Multiple Myeloma
Primary: Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria — 15.8; 20.0 percentage of participants
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants
Plasma Cell Myeloma · Multiple Myeloma
Primary: Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis — 98 percentage of…
Multiple Myeloma · Chronic Kidney Disease
Primary: Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain — 13; 3 Participants — p=0.006
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Multiple Myeloma
Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants
Plasma Cell Leukemia · Plasma Cell Myeloma · Plasmacytoma
Primary: Confirmed Response Rate — 0.06 proportion of patients
Smoldering Multiple Myeloma
Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants
Smoldering Multiple Myeloma
Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants
Plasma Cell Disorder
Primary: Positive for Hepatitis B Surface Antigen — 4; 3 participants
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Multiple Myeloma
Primary: The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction…
Smoldering Myeloma · Smoldering Multiple Myeloma
Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Multiple Myeloma
Primary: Complete Response Rate — 7; 7 Participants
Light Chain Deposition Disease · Primary Systemic Amyloidosis
Primary: Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR])…
Multiple Myeloma
Primary: Overall Response Rate — 6; 1; 20; 43 Participants
Multiple Myeloma
Primary: Progression Free Survival — 3; 9 participants
Multiple Myeloma
Primary: Objective Response Rate — 6; 16; 11; 10 Participants
Multiple Myeloma
Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants
Lymphoma · Mantle Cell Lymphoma · Indolent Lymphoma
Primary: Progression-free Survival at 2 Years — 15 Participants